Karuna’s New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults was accepted for review by the US ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 0.1% during trading on Friday after Citigroup raised their price target on the stock from $215.00 to $226.00. Citigroup currently has a ...

UChicago Medicine has received a $75 million gift from the AbbVie Foundation — a nonprofit focused on advancing health equity — to support the development of its new 575,000-square-foot cancer ...

University of Chicago Medicine has received a $75 million donation from the AbbVie Foundation to help it build its massive ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Wednesday reported third-quarter profit of $1.56 billion.

In this review, we summarise the current knowledge on IBS-like symptoms ... Competing interests JW has no conflict of ...

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).